Cargando…

Potential protective and therapeutic role of immune checkpoint inhibitors against viral infections and COVID-19

Detalles Bibliográficos
Autores principales:	Gatto, Lidia, Franceschi, Enrico, Nunno, Vincenzo Di, Brandes, Alba Ariela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Medicine Ltd 2020
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325496/ https://www.ncbi.nlm.nih.gov/pubmed/32594820 http://dx.doi.org/10.2217/imt-2020-0109

Ejemplares similares

Glioblastoma Microenvironment: From an Inviolable Defense to a Therapeutic Chance
por: Di Nunno, Vincenzo, et al.
Publicado: (2022)

Molecular Targeted Therapies: Time for a Paradigm Shift in Medulloblastoma Treatment?
por: Gatto, Lidia, et al.
Publicado: (2022)

Tumor-Associated Microenvironment of Adult Gliomas: A Review
por: Di Nunno, Vincenzo, et al.
Publicado: (2022)

Discovering the Molecular Landscape of Meningioma: The Struggle to Find New Therapeutic Targets
por: Maggio, Ilaria, et al.
Publicado: (2021)

Glioblastoma: Emerging Treatments and Novel Trial Designs
por: Di Nunno, Vincenzo, et al.
Publicado: (2021)

Beyond Imaging and Genetic Signature in Glioblastoma: Radiogenomic Holistic Approach in Neuro-Oncology
por: Gatto, Lidia, et al.
Publicado: (2022)

Distinct MRI pattern of “pseudoresponse” in recurrent glioblastoma multiforme treated with regorafenib: Case report and literature review
por: Gatto, Lidia, et al.
Publicado: (2021)

Meningioma: not always a benign tumor. A review of advances in the treatment of meningiomas
por: Maggio, Ilaria, et al.
Publicado: (2021)

IDH1 Non-Canonical Mutations and Survival in Patients with Glioma
por: Franceschi, Enrico, et al.
Publicado: (2021)

Implications of BRAF V600E mutation in gliomas: Molecular considerations, prognostic value and treatment evolution
por: Di Nunno, Vincenzo, et al.
Publicado: (2023)

The Risk Assessment in Low-Grade Gliomas: An Analysis of the European Organization for Research and Treatment of Cancer (EORTC) and the Radiation Therapy Oncology Group (RTOG) criteria
por: Lanese, Andrea, et al.
Publicado: (2018)

DCVax-L Vaccination in Patients with Glioblastoma: Real Promise or Negative Trial? The Debate Is Open
por: Gatto, Lidia, et al.
Publicado: (2023)

Tumor Microenvironment in Gliomas: A Treatment Hurdle or an Opportunity to Grab?
por: Di Nunno, Vincenzo, et al.
Publicado: (2023)

CAR-T cells neurotoxicity from consolidated practice in hematological malignancies to fledgling experience in CNS tumors: fill the gap
por: Gatto, Lidia, et al.
Publicado: (2023)

Olfactory neuroblastoma: diagnosis, management, and current treatment options
por: Tosoni, Alicia, et al.
Publicado: (2023)

Consideration of Severe Coronavirus Disease 2019 As Viral Sepsis and Potential Use of Immune Checkpoint Inhibitors
por: Odabasi, Zekaver, et al.
Publicado: (2020)

The gut microbiota and immune checkpoint inhibitors
por: Humphries, Audrey, et al.
Publicado: (2018)

Immune checkpoint inhibitor-related acral vasculitis
por: Comont, Thibault, et al.
Publicado: (2018)

Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
por: Adashek, Jacob J., et al.
Publicado: (2019)

Is there a role for therapeutic cancer vaccines in the age of checkpoint inhibitors?
por: Dillman, Robert O.
Publicado: (2016)

Lessons From the Development of the Immune Checkpoint Inhibitors in Oncology
por: Jardim, Denis L., et al.
Publicado: (2018)

Antibiotic therapy and outcome from immune-checkpoint inhibitors
por: Pinato, David J., et al.
Publicado: (2019)

COVID-19 and immune checkpoint inhibitors: initial considerations
por: Sullivan, Ryan J, et al.
Publicado: (2020)

Immune checkpoint inhibitors: here to stay
por: Carvalho, Filomena Marino, et al.
Publicado: (2023)

Campylobacteriosis following immunosuppression for immune checkpoint inhibitor-related toxicity
por: Lee, Karla A, et al.
Publicado: (2020)

Major hurdles of immune-checkpoint inhibitors in pancreatic ductal adenocarcinoma
por: Akhuba, Liia, et al.
Publicado: (2023)

Association of immune-related adverse events with immune checkpoint inhibitor efficacy: real or imaginary?
por: Haratani, Koji, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors and Radiotherapy in NSCLC Patients: Not Just a Fluke
por: Belluomini, Lorenzo, et al.
Publicado: (2019)

Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors
por: Bersanelli, Melissa
Publicado: (2020)

How Compatible Are Immune Checkpoint Inhibitors and Thermal Ablation for Liver Metastases?
por: Minami, Yasunori, et al.
Publicado: (2022)

Combining STAT3-Targeting Agents with Immune Checkpoint Inhibitors in NSCLC
por: Papavassiliou, Kostas A., et al.
Publicado: (2023)

Systemic immune parameters after prior radiation therapy in patients receiving immune checkpoint inhibitors
por: Mundra, Vatsala, et al.
Publicado: (2023)

Immune checkpoint inhibitor induced neurocognitive deficits in patients
por: Zeiser, Robert, et al.
Publicado: (2023)

Therapeutic Approaches With Immune Checkpoint Inhibitors in Head and Neck Cancers and the Role of PD-L1 as a Biomarker
por: Oualla, Karima, et al.
Publicado: (2021)

A New Molecular Taxonomy to Predict Immune Checkpoint Inhibitor Sensitivity in Prostate Cancer
por: Antonarakis, Emmanuel S.
Publicado: (2019)

Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of Cancer
por: Yu, Peter Paul, et al.
Publicado: (2019)

A Multidisciplinary Approach for Patients with Preexisting Lung Diseases and Immune Checkpoint Inhibitor Toxicities
por: Naidoo, Jarushka, et al.
Publicado: (2020)

Pneumonitis from immune checkpoint inhibitors and COVID-19: current concern in cancer treatment
por: Rossi, Ernesto, et al.
Publicado: (2020)

Immune checkpoint inhibitor-related hypogonadism and infertility: a neglected issue in immuno-oncology
por: Özdemir, Berna C
Publicado: (2021)

Cardiovascular toxicity following immune checkpoint inhibitors: A systematic review and meta-analysis
por: Xavier, Camila Bragança, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_df6l7kmb4k3oodja1f5ijv9kgr